Pioglitazone, Bladder Cancer, and the Presumption of Innocence

Georgios   S.   Papaetis
Abstract

Background: Thiazolidinediones are potent exogenous agonists of PPAR-γ that augment the effects of insulin to its cellular targets, mainly at the level of adipose tissue. Pioglitazone, the main thiazolidinedione in clinical practice, has shown cardiovascular and renal benefits in patients with type 2 diabetes, durable reduction of glycated hemoglobulin levels, important improvements of several components of the metabolic syndrome, and beneficial effects of non-alcoholic fatty liver disease.
Objective: Despite all of its established advantages, the controversy for an increased risk of developing bladder cancer, combined with the advent of newer drug classes that achieved major cardiorenal effects, have significantly limited its use spreading a persistent shadow of doubt for its future role.
Methods: Pubmed, Google, and Scope databases have been thoroughly searched, and relevant studies were selected.
Results: This paper thoroughly explores both in vitro and in vivo (animal models and humans) studies that investigated the possible association of pioglitazone with bladder cancer.
Conclusion: Currently, the association of pioglitazone with bladder cancer cannot be based on solid evidence. This evidence cannot justify its low clinical administration, especially in the present era of individualised treatment strategies. Definite clarification of this issue is imperative and urgently anticipated from future high quality and rigorous pharmacoepidemiologic research, keeping in mind its unique mechanism of action and its significant pleiotropic effects.
Keywords: Pioglitazone, thiazolidinediones, bladder cancer, diabetes mellitus, insulin resistance, pharmacoepi demiology.
Graphical Abstract

[1] 
Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: From cellular targets to cardiovascular benefit. Curr Drug Targets  2011; 12(10): 1498-512.
[http://dx.doi.org/10.2174/138945011796818243] [PMID:  21675944] 
[2] 
Bays H, Mandarino L, DeFronzo RA. Role of the adipocytes, FFA, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: PPAR agonists provide a rational therapeutic approach. J Clin Endocrinol Metab  2004; 89(2): 463-78.
[http://dx.doi.org/10.1210/jc.2003-030723] [PMID:  14764748] 
[3] 
Wang S, Dougherty EJ, Danner RL. PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res  2016; 111: 76-85.
[http://dx.doi.org/10.1016/j.phrs.2016.02.028] [PMID:  27268145] 
[4] 
Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev  2002; 18(Suppl. 2): S10-5.
[http://dx.doi.org/10.1002/dmrr.249] [PMID:  11921433] 
[5] 
Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci  2015; 11(3): 463-82.
[http://dx.doi.org/10.5114/aoms.2015.52350] [PMID:  26170839] 
[6] 
Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study. J Am Coll Cardiol  2005; 45(12): 1925-31.
[http://dx.doi.org/10.1016/j.jacc.2005.03.041] [PMID:  15963388] 
[7] 
DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res  2019; 16(2): 133-43.
[http://dx.doi.org/10.1177/1479164118825376] [PMID:  30706731] 
[8] 
Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of prediabetes in clinical practice: Targeting insulin resistance and β-cell dysfunction. Endocr Pract  2012; 18(3): 342-50.
[http://dx.doi.org/10.4158/EP11194.OR] [PMID:  22068250] 
[9] 
Tripathy D, Schwenke DC, Banerji M, et al. Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: Results from act now. J Clin Endocrinol Metab  2016; 101(5): 2056-62.
[http://dx.doi.org/10.1210/jc.2015-4202] [PMID:  26982008] 
[10] 
Stringer F, DeJongh J, Enya K, Koumura E, Danhof M, Kaku K. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes. Diabetes Technol Ther  2015; 17(3): 215-23.
[http://dx.doi.org/10.1089/dia.2014.0222] [PMID:  25531677] 
[11] 
Vu A, Kosmiski LA, Beitelshees AL, et al. Pharmacodynamic effects of low-dose pioglitazone in patients with the metabolic syndrome without diabetes mellitus. Pharmacotherapy  2016; 36(3): 252-62.
[http://dx.doi.org/10.1002/phar.1713] [PMID:  26822630] 
[12] 
Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am J Kidney Dis  2010; 55(5): 835-47.
[http://dx.doi.org/10.1053/j.ajkd.2009.11.013] [PMID:  20110146] 
[13] 
Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med  2016; 165(5): 305-15.
[http://dx.doi.org/10.7326/M15-1774] [PMID:  27322798] 
[14] 
Panunzi S, Maltese S, Verrastro O, et al. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes Metab  2021; 23(4): 980-90.
[http://dx.doi.org/10.1111/dom.14304] [PMID:  33368954] 
[15] 
Yen CL, Wu CY, See LC, et al. Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National cohort study. Diabetes Care  2020; 43(10): e152-3.
[http://dx.doi.org/10.2337/dc20-1584] [PMID:  32801131] 
[16] 
Fiorentino TV, Monroy A, Kamath S, et al. Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. Metabolism  2021; 114: 154416.
[http://dx.doi.org/10.1016/j.metabol.2020.154416] [PMID:  33137378] 
[17] 
Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ  2012; 345: e4541.
[http://dx.doi.org/10.1136/bmj.e4541] [PMID:  22763399] 
[18] 
Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: Angel or demon? Curr Pharm Des  2013; 19(27): 4913-29.
[http://dx.doi.org/10.2174/13816128113199990294] [PMID:  23278487] 
[19] 
Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML. Use of thiazolidinediones and risk of bladder cancer: Disease or drugs? Curr Drug Saf  2013; 8(5): 364-70.
[http://dx.doi.org/10.2174/15748863113086660069] [PMID:  24215315] 
[20] 
Fernandez-Fernandez B, Sarafidis P, Kanbay M, et al. SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia. Clin Kidney J  2020; 13(5): 728-33.
[http://dx.doi.org/10.1093/ckj/sfaa198] [PMID:  33123352] 
[21] 
Papaetis GS. Empagliflozin and the diabetic kidney: Pathophysiological concepts and future challenges. Endocr Metab Immune Disord Drug Targets  2021; 21(9): 1555-89.
[http://dx.doi.org/10.2174/1871530321999201214233421] [PMID:  33319678] 
[22] 
Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes  2014; 5(6): 817-34.
[http://dx.doi.org/10.4239/wjd.v5.i6.817] [PMID:  25512784] 
[23] 
Papaetis GS. Liraglutide therapy in a prediabetic state: Rethinking the evidence. Curr Diabetes Rev  2020; 16(7): 699-715.
[http://dx.doi.org/10.2174/1573399816666191230113446] [PMID:  31886752] 
[24] 
Papaetis GS, Filippou PK, Constantinidou KG, Stylianou CS. Liraglutide: New perspectives for the treatment of polycystic ovary syndrome. Clin Drug Investig  2020; 40(8): 695-713.
[http://dx.doi.org/10.1007/s40261-020-00942-2] [PMID:  32583294] 
[25] 
Davidson MB. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications  2016; 30(6): 981-5.
[http://dx.doi.org/10.1016/j.jdiacomp.2016.04.004] [PMID:  27133452] 
[26] 
Sinha B, Ghosal S. Pioglitazone--do we really need it to manage type 2 diabetes? Diabetes Metab Syndr  2013; 7(4): 243-6.
[http://dx.doi.org/10.1016/j.dsx.2013.06.005] [PMID:  24290093] 
[27] 
Grosse Y, Loomis D, Lauby-Secretan B, et al. International agency for research on cancer monograph working group. Carcinogenicity of some drugs and herbal products. Lancet Oncol  2013; 14(9): 807-8.
[http://dx.doi.org/10.1016/S1470-2045(13)70329-2] [PMID:  24058961] 
[28] 
Engler C, Leo M, Pfeifer B, et al. Long-term trends in the prescription of antidiabetic drugs: Real-world evidence from the Diabetes Registry Tyrol 2012-2018. BMJ Open Diabetes Res Care  2020; 8(1): e001279.
[http://dx.doi.org/10.1136/bmjdrc-2020-001279] [PMID:  32873600] 
[29] 
Cid Ruzafa J, Ulrichsen SP, Bennett D, Ehrenstein V. Post-authorisation safety study of pioglitazone use and safety endpoints of interest in Denmark after direct healthcare professional communication. Drugs Real World Outcomes  2019; 6(3): 133-40.
[http://dx.doi.org/10.1007/s40801-019-0160-6] [PMID:  31376066] 
[30] 
Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes  1998; 47(4): 507-14.
[http://dx.doi.org/10.2337/diabetes.47.4.507] [PMID:  9568680] 
[31] 
Christodoulides C, Vidal-Puig A. PPARs and adipocyte function. Mol Cell Endocrinol  2010; 318(1-2): 61-8.
[http://dx.doi.org/10.1016/j.mce.2009.09.014] [PMID:  19772894] 
[32] 
Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol  1997; 273(6): F1013-22.
[PMID:  9435691] 
[33] 
Jain S, Pulikuri S, Zhu Y, et al. Differential expression of the peroxisome proliferator-activated receptor γ (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol  1998; 153(2): 349-54.
[http://dx.doi.org/10.1016/S0002-9440(10)65577-0] [PMID:  9708794] 
[34] 
Liu C, Tate T, Batourina E, et al. Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells. Nat Commun  2019; 10(1): 4589.
[http://dx.doi.org/10.1038/s41467-019-12332-0] [PMID:  31597917] 
[35] 
Shu L, Huang R, Wu S, et al. PPARgamma and its ligands: Potential antitumor agents in the digestive system. Curr Stem Cell Res Ther  2016; 11: 274-81.
[http://dx.doi.org/10.2174/1574888X10666150630111618] [PMID:  26122910] 
[36] 
Yousefnia S, Momenzadeh S, Seyed Forootan F, Ghaedi K, Nasr Esfahani MH. The influence of Peroxisome Proliferator-Activated Receptor γ (PPARγ) ligands on cancer cell tumorigenicity. Gene  2018; 649: 14-22.
[http://dx.doi.org/10.1016/j.gene.2018.01.018] [PMID:  29369787] 
[37] 
Mushtaq J, Thurairaja R, Nair R. Bladder cancer. Surgery  2019; 37(9): 529-37.
[http://dx.doi.org/10.1016/j.mpsur.2019.07.003] 
[38] 
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel)  2020; 8(1): 15.
[http://dx.doi.org/10.3390/medsci8010015] [PMID:  32183076] 
[39] 
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell  2014; 25(2): 152-65.
[http://dx.doi.org/10.1016/j.ccr.2014.01.009] [PMID:  24525232] 
[40] 
Fong MHY, Feng M, McConkey DJ, Choi W. Update on bladder cancer molecular subtypes. Transl Androl Urol  2020; 9(6): 2881-9.
[http://dx.doi.org/10.21037/tau-2019-mibc-12] [PMID:  33457262] 
[41] 
Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res  2005; 11(11): 4044-55.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-2409] [PMID:  15930339] 
[42] 
Dadhania V, Zhang M, Zhang L, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine  2016; 12: 105-17.
[http://dx.doi.org/10.1016/j.ebiom.2016.08.036] [PMID:  27612592] 
[43] 
Biton A, Bernard-Pierrot I, Lou Y, et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep  2014; 9(4): 1235-45.
[http://dx.doi.org/10.1016/j.celrep.2014.10.035] [PMID:  25456126] 
[44] 
Goldstein JT, Berger AC, Shih J, et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res  2017; 77(24): 6987-98.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-1701] [PMID:  28923856] 
[45] 
Cheng S, Qian K, Wang Y, et al. PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. J Cell Mol Med  2019; 23(5): 3724-36.
[http://dx.doi.org/10.1111/jcmm.14280] [PMID:  30912275] 
[46] 
Peng T, Wang G, Cheng S, et al. The role and function of PPARγ in bladder cancer. J Cancer  2020; 11(13): 3965-75.
[http://dx.doi.org/10.7150/jca.42663] [PMID:  32328200] 
[47] 
Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem  2002; 277(26): 23534-43.
[http://dx.doi.org/10.1074/jbc.M200172200] [PMID:  11980898] 
[48] 
Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers  2005; 10(4): 295-309.
[http://dx.doi.org/10.1080/13547500500218682] [PMID:  16240504] 
[49] 
Zhang Z, Xu H, Ji J, et al. Heterogeneity of PTEN and PPAR-γ in cancer and their prognostic application to bladder cancer. Exp Ther Med  2019; 18(4): 3177-83.
[http://dx.doi.org/10.3892/etm.2019.7879] [PMID:  31555390] 
[50] 
Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of Peroxisome Proliferator-Activated Receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer  2003; 104(5): 597-602.
[http://dx.doi.org/10.1002/ijc.10980] [PMID:  12594814] 
[51] 
Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol  2001; 159(2): 591-7.
[http://dx.doi.org/10.1016/S0002-9440(10)61730-0] [PMID:  11485917] 
[52] 
Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer  2006; 6: 53.
[http://dx.doi.org/10.1186/1471-2407-6-53] [PMID:  16519808] 
[53] 
Lv S, Wang W, Wang H, Zhu Y, Lei C. PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer  2019; 19(1): 204.
[http://dx.doi.org/10.1186/s12885-019-5426-6] [PMID:  30845932] 
[54] 
Rochel N, Krucker C, Coutos-Thévenot L, et al. Recurrent activating mutations of PPARγ associated with luminal bladder tumors. Nat Commun  2019; 10(1): 253.
[http://dx.doi.org/10.1038/s41467-018-08157-y] [PMID:  30651555] 
[55] 
Korpal M, Puyang X, Jeremy Wu Z, et al. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. Nat Commun  2017; 8(1): 103.
[http://dx.doi.org/10.1038/s41467-017-00147-w] [PMID:  28740126] 
[56] 
Lodillinsky C, Umerez MS, Jasnis MA, Casabé A, Sandes E, Eiján AM. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells. Int J Mol Med  2006; 17(2): 269-73.
[http://dx.doi.org/10.3892/ijmm.17.2.269] [PMID:  16391825] 
[57] 
Langle Y, Lodillinsky C, Belgorosky D, Sandes EO, Eiján AM. Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy. J Urol  2012; 188(6): 2384-90.
[http://dx.doi.org/10.1016/j.juro.2012.07.109] [PMID:  23088980] 
[58] 
Rebouissou S, Bernard-Pierrot I, de Reyniès A, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med  2014; 6(244): 244ra91.
[http://dx.doi.org/10.1126/scitranslmed.3008970] [PMID:  25009231] 
[59] 
Mansure JJ, Nassim R, Chevalier S, et al. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PLoS One  2013; 8(2): e55997.
[http://dx.doi.org/10.1371/journal.pone.0055997] [PMID:  23409107] 
[60] 
Mehus AA, Bergum N, Knutson P, et al. Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One  2020; 15(8): e0237976.
[http://dx.doi.org/10.1371/journal.pone.0237976] [PMID:  32822399] 
[61] 
Wang G, Cao R, Wang Y, et al. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. Sci Rep  2016; 6: 35783.
[http://dx.doi.org/10.1038/srep35783] [PMID:  27779188] 
[62] 
Cheng S, Wang G, Wang Y, et al. Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer. Clin Sci (Lond)  2019; 133(15): 1745-58.
[http://dx.doi.org/10.1042/CS20190587] [PMID:  31358595] 
[63] 
Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci  2010; 113(2): 349-57.
[http://dx.doi.org/10.1093/toxsci/kfp256] [PMID:  19858066] 
[64] 
Yang SL, Wang JJ, Chen M, et al. Pioglitazone use and risk of bladder cancer: An in vitro study. Int J Med Sci  2018; 15(3): 228-37.
[http://dx.doi.org/10.7150/ijms.22408] [PMID:  29483814] 
[65] 
Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res  1992; 52(6): 1393-8.
[PMID:  1540947] 
[66] 
Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol  1994; 152(2 Pt 1): 388-92.
[http://dx.doi.org/10.1016/S0022-5347(17)32745-3] [PMID:  8015077] 
[67] 
Kopparapu PK, Boorjian SA, Robinson BD, et al. Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res  2013; 33(12): 5235-42.
[PMID:  24324055] 
[68] 
Shahid M, Kim M, Yeon A, et al. Pioglitazone alters the proteomes of normal bladder epithelial cells but shows no tumorigenic effects. Int Neurourol J  2020; 24(1): 29-40.
[http://dx.doi.org/10.5213/inj.1938186.093] [PMID:  32252184] 
[69] 
Han Y, Jin X, Zhou H, Liu B. Identification of key genes associated with bladder cancer using gene expression profiles. Oncol Lett  2018; 15(1): 297-303.
[PMID:  29375713] 
[70] 
Kim D, Ahn BN, Kim Y, et al. High glucose with insulin induces cell cycle progression and activation of oncogenic signaling of bladder epithelial cells cotreated with metformin and pioglitazone. J Diabetes Res  2019; 2019: 2376512.
[http://dx.doi.org/10.1155/2019/2376512] [PMID:  30729133] 
[71] 
Atlı Şekeroğlu Z, Şekeroğlu V, Kontaş Yedier S, İlkun E, Liou LS. Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone. Environ Mol Mutagen  2021; 62(2): 143-54.
[http://dx.doi.org/10.1002/em.22424] [PMID:  33496997] 
[72] 
Sakamoto J, Kimura H, Moriyama S, et al. Activation of human Peroxisome Proliferator-Activated Receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun  2000; 278(3): 704-11.
[http://dx.doi.org/10.1006/bbrc.2000.3868] [PMID:  11095972] 
[73] 
Orasanu G, Ziouzenkova O, Devchand PR, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol  2008; 52(10): 869-81.
[http://dx.doi.org/10.1016/j.jacc.2008.04.055] [PMID:  18755353] 
[74] 
Oleksiewicz MB, Southgate J, Iversen L, Egerod FL. Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists. PPAR Res  2008; 2008: 103167.
[http://dx.doi.org/10.1155/2008/103167] [PMID:  19197366] 
[75] 
Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer  2008; 123(10): 2254-9.
[http://dx.doi.org/10.1002/ijc.23765] [PMID:  18712722] 
[76] 
Tirmenstein M, Janovitz E, Dorr T, et al. Evaluation of uracil, sodium ascorbate, and rosiglitazone as promoters of urinary bladder transitional cell carcinomas in male Sprague-Dawley rats. Toxicol Pathol  2018; 46(2): 147-57.
[http://dx.doi.org/10.1177/0192623318756004] [PMID:  29471778] 
[77] 
Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci  2005; 87(2): 322-7.
[http://dx.doi.org/10.1093/toxsci/kfi266] [PMID:  16049269] 
[78] 
Hardisty JF, Anderson DC, Brodie S, et al. Histopathology of the urinary bladders of cynomolgus monkeys treated with PPAR agonists. Toxicol Pathol  2008; 36(6): 769-76.
[http://dx.doi.org/10.1177/0192623308323624] [PMID:  18776159] 
[79] 
Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol  2006; 34(7): 903-20.
[http://dx.doi.org/10.1080/01926230601072327] [PMID:  17178691] 
[80] 
Van Vleet TR, White MR, Sanderson TP, et al. Subchronic urinary bladder effects of muraglitazar in male rats. Toxicol Sci  2007; 96(1): 58-71.
[http://dx.doi.org/10.1093/toxsci/kfl176] [PMID:  17132713] 
[81] 
Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: Lack of evidence for urolithiasis as an inciting event. Toxicol Pathol  2008; 36(2): 218-31.
[http://dx.doi.org/10.1177/0192623307311757] [PMID:  18474944] 
[82] 
Lima BS, Dominick M, Iversen L, Oleksiewicz MB.  Peroxisome proliferators activated receptors (PPARs) agonists and rodent tumorigenesis: updating the discussions Proceedings of the 42nd DIA Annual Meeting. Philadelphia, Pa, USA. BT Biotechnology/ NC Nonclinical Labaroratory Safety, 299D 2006.
[83] 
Varley CL, Southgate J. Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol  2008; 60(6): 435-41.
[http://dx.doi.org/10.1016/j.etp.2008.04.009] [PMID:  18571911] 
[84] 
Varley CL, Stahlschmidt J, Lee WC, et al. Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci  2004; 117(Pt 10): 2029-36.
[http://dx.doi.org/10.1242/jcs.01042] [PMID:  15054105] 
[85] 
Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: Lessons from animal studies. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev  2012; 30(4): 368-402.
[http://dx.doi.org/10.1080/10590501.2012.735519] [PMID:  23167631] 
[86] 
Mahal A, Young-Lin N, Dobberfuhl A, Estes J, Comiter CV. Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model. Investig Clin Urol  2018; 59(4): 257-62.
[http://dx.doi.org/10.4111/icu.2018.59.4.257] [PMID:  29984341] 
[87] 
Sato K, Awasaki Y, Kandori H, et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol  2011; 251(3): 234-44.
[http://dx.doi.org/10.1016/j.taap.2011.01.006] [PMID:  21255596] 
[88] 
Achanzar WE, Moyer CF, Marthaler LT, et al. Urine acidification has no effect on Peroxisome Proliferator-Activated Receptor (PPAR) signaling or Epidermal Growth Factor (EGF) expression in rat urinary bladder urothelium. Toxicol Appl Pharmacol  2007; 223(3): 246-56.
[http://dx.doi.org/10.1016/j.taap.2007.06.015] [PMID:  17663016] 
[89] 
La Maestra S, Micale RT, De Flora S, et al. DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents. Carcinogenesis  2013; 34(1): 183-9.
[http://dx.doi.org/10.1093/carcin/bgs314] [PMID:  23042096] 
[90] 
Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients withtype 2 diabetes in the PROactive Study (PROspective pioglitAzoneClinical Trial in macroVascular Events): A randomised controlled trial. Lancet  2005; 366(9493): 1279-89.
[http://dx.doi.org/10.1016/S0140-6736(05)67528-9] [PMID:  16214598] 
[91] 
Ryder REJ. Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes. Br J Diabetes Vasc Dis  2011; 11(3): 113-20.
[http://dx.doi.org/10.1177/1474651411412658] 
[92] 
Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke  2007; 38(3): 865-73.
[http://dx.doi.org/10.1161/01.STR.0000257974.06317.49] [PMID:  17290029] 
[93] 
Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol  2007; 49(17): 1772-80.
[http://dx.doi.org/10.1016/j.jacc.2006.12.048] [PMID:  17466227] 
[94] 
Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L. PROactive investigators. Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis  2009; 202(1): 272-81.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.03.002] [PMID:  18538774] 
[95] 
Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D. Scientific evidence and controversies about pioglitazone and bladder cancer: Which lessons can be drawn? Drug Saf  2013; 36(9): 693-707.
[http://dx.doi.org/10.1007/s40264-013-0086-y] [PMID:  23868339] 
[96] 
Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet  2011; 378(9802): 1543-4.
[http://dx.doi.org/10.1016/S0140-6736(11)61662-0] [PMID:  22035550] 
[97] 
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf  2009; 32(3): 187-202.
[http://dx.doi.org/10.2165/00002018-200932030-00002] [PMID:  19338377] 
[98] 
Ryder RE. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. Diabet Med  2015; 32(4): 438-9.
[http://dx.doi.org/10.1111/dme.12703] [PMID:  25773281] 
[99] 
Ryder RE. Pioglitazone: Reports of its death are greatly exaggerated - it is alive and ready to resume saving lives. Diabet Med  2015; 32(4): e9-e15.
[http://dx.doi.org/10.1111/dme.12736] [PMID:  25773282] 
[100] 
Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, Perez A. Observational follow-up of the PROactive study: A 6-year update. Diabetes Obes Metab  2014; 16(1): 63-74.
[http://dx.doi.org/10.1111/dom.12180] [PMID:  23859428] 
[101] 
Erdmann E, Harding S, Lam H, Perez A. Ten-year observational follow-up of PROactive: A randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab  2016; 18(3): 266-73.
[http://dx.doi.org/10.1111/dom.12608] [PMID:  26592506] 
[102] 
Gale EA. Pioglitazone: Are rumours of its death exaggerated? Diabet Med  2015; 32(4): 431-7.
[http://dx.doi.org/10.1111/dme.12708] [PMID:  25773280] 
[103] 
Kernan WN, Viscoli CM, Furie KL, et al. IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med  2016; 374(14): 1321-31.
[http://dx.doi.org/10.1056/NEJMoa1506930] [PMID:  26886418] 
[104] 
Spence JD, Viscoli CM, Inzucchi SE, et al. IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: A post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol  2019; 76(5): 526-35.
[http://dx.doi.org/10.1001/jamaneurol.2019.0079] [PMID:  30734043] 
[105] 
Vaccaro O, Masulli M, Nicolucci A, et al. Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): A randomised, multicentre trial. Lancet Diabetes Endocrinol  2017; 5(11): 887-97.
[http://dx.doi.org/10.1016/S2213-8587(17)30317-0] [PMID:  28917544] 
[106] 
Yoshii H, Onuma T, Yamazaki T, et al. PROFIT-J Study group. Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: The PROFIT-J study. J Atheroscler Thromb  2014; 21(6): 563-73.
[http://dx.doi.org/10.5551/jat.21626] [PMID:  24477028] 
[107] 
Tanaka R, Yamashiro K, Okuma Y, et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: The J-SPIRIT study. J Atheroscler Thromb  2015; 22(12): 1305-16.
[http://dx.doi.org/10.5551/jat.30007] [PMID:  26269002] 
[108] 
DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med  2011; 364(12): 1104-15.
[http://dx.doi.org/10.1056/NEJMoa1010949] [PMID:  21428766] 
[109] 
Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol  2013; 33(2): 393-9.
[http://dx.doi.org/10.1161/ATVBAHA.112.300346] [PMID:  23175674] 
[110] 
Kaku K, Daida H, Kashiwagi A, et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin  2009; 25(12): 2925-32.
[http://dx.doi.org/10.1185/03007990903328124] [PMID:  19835463] 
[111] 
Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis. BMJ Open  2017; 7(1): e013927.
[http://dx.doi.org/10.1136/bmjopen-2016-013927] [PMID:  28057658] 
[112] 
Sinha B, Ghosal S. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: A meta-analysis of its risks and benefits from prospective trials. Sci Rep  2020; 10(1): 15781.
[http://dx.doi.org/10.1038/s41598-020-72967-8] [PMID:  32978507] 
[113] 
Alam F, Islam MA, Mohamed M, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: A systematic review and meta-analysis of randomised controlled trials. Sci Rep  2019; 9(1): 5389.
[http://dx.doi.org/10.1038/s41598-019-41854-2] [PMID:  30926892] 
[114] 
Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care  2011; 34(4): 916-22.
[http://dx.doi.org/10.2337/dc10-1068] [PMID:  21447663] 
[115] 
Friedman G, Habel L, Boles M, Mcfarland B. Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division Pharmacoepidemiology.  3rd ed. West Sussex, U.K.: John Wiley & Sons 2000; pp. 263-83.
[http://dx.doi.org/10.1002/0470842555.ch16] 
[116] 
Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care  2011; 34(4): 923-9.
[http://dx.doi.org/10.2337/dc10-1067] [PMID:  21447664] 
[117] 
Yang X, Chan JC. Comment: Analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care  2011; 34(8): e136.
[http://dx.doi.org/10.2337/dc11-0627] [PMID:  21788639] 
[118] 
 FDA. Drug Safety Communication: Ongoing Safety Review of
Actos (pioglitazone) and Potential Increased Risk of Bladder
Cancer After Two Years Exposure. Available from: http://www.fda.gov/Drugs/ (Accessed April 29, 2015)
[119] 
 European Medicines Agency. European Medicines Agency
recommends new contra-indications and warnings for pioglitazone to
reduce small increased risk of bladder cancer. 2011. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5cl (Accessed on 12 October, 2013).
[120] 
Lewis JD, Habel L, Quesenberry C, et al. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: Potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf  2014; 23(6): 636-45.
[http://dx.doi.org/10.1002/pds.3619] [PMID:  24764283] 
[121] 
Dolin P. Pioglitazone, bladder cancer, and detection bias. J Diabetes  2014; 6(2): 193-4.
[http://dx.doi.org/10.1111/1753-0407.12087] [PMID:  24004505] 
[122] 
Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia  2012; 55(7): 1953-62.
[http://dx.doi.org/10.1007/s00125-012-2538-9] [PMID:  22460763] 
[123] 
 French medicines agency (AFSSAPS) (2011) Use of medications
containing pioglitazone (Actos®, Competact®) Suspended. 2011.
Available from: www.afssaps.fr/content/download/34175/447382/version/1/file/Press-release-Suspension-Pioglitazone.pdf (Accessed
12 August, 2011).
[124] 
Sadikot SM, Ghosal S. India suspends pioglitazone: Is it justified? Diabetes Metab Syndr  2014; 8(1): 53-6.
[http://dx.doi.org/10.1016/j.dsx.2013.10.020] [PMID:  24661760] 
[125] 
Singh AK. Polemics of pioglitazone: An appraisal in 2015. Expert Rev Endocrinol Metab  2015; 10(4): 447-58.
[http://dx.doi.org/10.1586/17446651.2015.1054809] [PMID:  30293494] 
[126] 
Perez AT. Pioglitazone and risk of bladder cancer: Clarification of the design of the French study. Diabetologia  2013; 56(1): 227.
[http://dx.doi.org/10.1007/s00125-012-2767-y] [PMID:  23135221] 
[127] 
Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care  2011; 34(6): 1369-71.
[http://dx.doi.org/10.2337/dc10-2412] [PMID:  21515844] 
[128] 
Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study. BMJ  2012; 344: e3645.
[http://dx.doi.org/10.1136/bmj.e3645] [PMID:  22653981] 
[129] 
Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: A propensity score matched cohort study. Br J Clin Pharmacol  2013; 75(1): 254-9.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04325.x] [PMID:  22574756] 
[130] 
Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study. J Natl Cancer Inst  2012; 104(18): 1411-21.
[http://dx.doi.org/10.1093/jnci/djs328] [PMID:  22878886] 
[131] 
Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: A meta-analysis. Diabetologia  2006; 49(12): 2819-23.
[http://dx.doi.org/10.1007/s00125-006-0468-0] [PMID:  17021919] 
[132] 
MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: Evidence from a case-control study in New England. Cancer  2011; 117(7): 1552-6.
[http://dx.doi.org/10.1002/cncr.25641] [PMID:  21425156] 
[133] 
Tseng CH. Pioglitazone and bladder cancer: A population-based study of Taiwanese. Diabetes Care  2012; 35(2): 278-80.
[http://dx.doi.org/10.2337/dc11-1449] [PMID:  22210574] 
[134] 
Tseng CH. Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan. Diabetologia  2011; 54(8): 2009-15.
[http://dx.doi.org/10.1007/s00125-011-2171-z] [PMID:  21544514] 
[135] 
Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci  2014; 30(2): 94-7.
[http://dx.doi.org/10.1016/j.kjms.2013.09.011] [PMID:  24444539] 
[136] 
Lee MY, Hsiao PJ, Yang YH, Lin KD, Shin SJ. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: Bladder cancer and chronic kidney disease. PLoS One  2014; 9(1): e85479.
[http://dx.doi.org/10.1371/journal.pone.0085479] [PMID:  24427312] 
[137] 
Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology  2012; 55(5): 1462-72.
[http://dx.doi.org/10.1002/hep.25509] [PMID:  22135104] 
[138] 
Tseng CH. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: A population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer  2013; 13: 7.
[http://dx.doi.org/10.1186/1471-2407-13-7] [PMID:  23286275] 
[139] 
Lin HC, Hsu YT, Kachingwe BH, Hsu CY, Uang YS, Wang LH. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: A six-year population-based cohort study. J Clin Pharm Ther  2014; 39(4): 354-60.
[http://dx.doi.org/10.1111/jcpt.12151] [PMID:  24661226] 
[140] 
Kao CH, Sun LM, Chen PC, et al. A population-based cohort study in Taiwan-use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol  2013; 24(2): 523-30.
[http://dx.doi.org/10.1093/annonc/mds472] [PMID:  23110810] 
[141] 
Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A nested case–control study. Drug Saf  2013; 36(8): 643-9.
[http://dx.doi.org/10.1007/s40264-013-0080-4] [PMID:  23797604] 
[142] 
Jin SM, Song SO, Jung CH, et al. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: A multi-center retrospective cohort study. J Korean Med Sci  2014; 29(2): 238-42.
[http://dx.doi.org/10.3346/jkms.2014.29.2.238] [PMID:  24550651] 
[143] 
Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J  2012; 36(5): 371-8.
[http://dx.doi.org/10.4093/dmj.2012.36.5.371] [PMID:  23130322] 
[144] 
Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig  2013; 33(9): 621-31.
[http://dx.doi.org/10.1007/s40261-013-0106-9] [PMID:  23881565] 
[145] 
Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr  2008; 2: 47-57.
[http://dx.doi.org/10.1016/j.dsx.2007.11.002] 
[146] 
Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: Results from the Vermont Diabetes Information System. BMC Med  2007; 5: 17.
[http://dx.doi.org/10.1186/1741-7015-5-17] [PMID:  17584937] 
[147] 
Sun GE, Wells BJ, Yip K, et al. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Diabetes Obes Metab  2014; 16(3): 276-83.
[http://dx.doi.org/10.1111/dom.12231] [PMID:  24199848] 
[148] 
Fujimoto K, Hamamoto Y, Honjo S, et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract  2013; 99(2): e21-3.
[http://dx.doi.org/10.1016/j.diabres.2012.11.013] [PMID:  23228390] 
[149] 
Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab  2014; 18(3): 425-7.
[http://dx.doi.org/10.4103/2230-8210.131223] [PMID:  24944944] 
[150] 
Riaz A, Khan K, Afreen B, Kazmi I. Bladder cancer in patients with type 2 diabetes treated with pioglitazone, a comparative study. J Ayub Med Coll Abbottabad  2018; 30(3): 356-9.
[PMID:  30465366] 
[151] 
Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA  2015; 314(3): 265-77.
[http://dx.doi.org/10.1001/jama.2015.7996] [PMID:  26197187] 
[152] 
Levin D, Bell S, Sund R, et al. Scottish Diabetes Research Network Epidemiology Group. Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia  2015; 58(3): 493-504.
[http://dx.doi.org/10.1007/s00125-014-3456-9] [PMID:  25481707] 
[153] 
Colhoun HM, Livingstone SJ, Looker HC, et al. Scottish Diabetes Research Network Epidemiology Group. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia  2012; 55(11): 2929-37.
[http://dx.doi.org/10.1007/s00125-012-2668-0] [PMID:  22945303] 
[154] 
Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: Retrospective cohort study using datasets from four European countries. BMJ  2016; 354: i3903.
[http://dx.doi.org/10.1136/bmj.i3903] [PMID:  27530399] 
[155] 
Strongman H, Korhonen P, Williams R, et al. Pioglitazone and risk of mortality in patients with type 2 diabetes: Results from a European multidatabase cohort study. BMJ Open Diabetes Res Care  2017; 5(1): e000364.
[http://dx.doi.org/10.1136/bmjdrc-2016-000364] [PMID:  28761650] 
[156] 
Strongman H, Christopher S, Majak M, et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: Extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care  2018; 6(1): e000481.
[http://dx.doi.org/10.1136/bmjdrc-2017-000481] [PMID:  29379607] 
[157] 
Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: Population based cohort study. BMJ  2016; 352: i1541.
[http://dx.doi.org/10.1136/bmj.i1541] [PMID:  27029385] 
[158] 
Han E, Jang SY, Kim G, et al. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine (Baltimore)  2016; 95(6): e2786.
[http://dx.doi.org/10.1097/MD.0000000000002786] [PMID:  26871835] 
[159] 
Mackenzie TA, Zaha R, Smith J, Karagas MR, Morden NE. Diabetes pharmacotherapies and bladder cancer: A medicare epidemiologic study. Diabetes Ther  2016; 7(1): 61-73.
[http://dx.doi.org/10.1007/s13300-016-0152-4] [PMID:  26894755] 
[160] 
Garry EM, Buse JB, Lund JL, Pate V, Stürmer T. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. Diabetes Obes Metab  2018; 20(1): 129-40.
[http://dx.doi.org/10.1111/dom.13049] [PMID:  28661561] 
[161] 
Garry EM, Buse JB, Gokhale M, et al. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. Diabetes Obes Metab  2019; 21(9): 2096-106.
[http://dx.doi.org/10.1111/dom.13774] [PMID:  31087620] 
[162] 
Gupta S, Gupta K, Ravi R, et al. Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study. Indian J Endocrinol Metab  2015; 19(5): 639-43.
[http://dx.doi.org/10.4103/2230-8210.163187] [PMID:  26425474] 
[163] 
Agrawal P, Jain A, Gautam A, Nigam AK, Pursnani N, Farooqui M. A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone. Perspect Clin Res  2021; 12(1): 9-13.
[http://dx.doi.org/10.4103/picr.PICR_192_18] [PMID:  33816203] 
[164] 
Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol  2008; 10(2): 120-35.
[PMID:  18660854] 
[165] 
Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med  2019; 36(1): 22-35.
[http://dx.doi.org/10.1111/dme.13854] [PMID:  30378165] 
[166] 
Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol  2003; 158(9): 915-20.
[http://dx.doi.org/10.1093/aje/kwg231] [PMID:  14585769] 
[167] 
Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab  2012; 38(6): 475-84.
[http://dx.doi.org/10.1016/j.diabet.2012.06.003] [PMID:  23041441] 
[168] 
Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract  2012; 98(1): 159-63.
[http://dx.doi.org/10.1016/j.diabres.2012.05.006] [PMID:  22705039] 
[169] 
Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: A meta-analysis. Oncologist  2013; 18(2): 148-56.
[http://dx.doi.org/10.1634/theoncologist.2012-0302] [PMID:  23345544] 
[170] 
Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies. Diabet Med  2013; 30(9): 1026-32.
[http://dx.doi.org/10.1111/dme.12144] [PMID:  23350856] 
[171] 
He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol  2014; 35(3): 2095-102.
[http://dx.doi.org/10.1007/s13277-013-1278-x] [PMID:  24092576] 
[172] 
Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis. Br J Clin Pharmacol  2014; 78(2): 258-73.
[http://dx.doi.org/10.1111/bcp.12306] [PMID:  24325197] 
[173] 
Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancer: Results of a meta-analysis of randomized clinical trials. Acta Diabetol  2014; 51(1): 91-101.
[http://dx.doi.org/10.1007/s00592-013-0504-8] [PMID:  23851465] 
[174] 
Qu H, Zheng Y, Wang Y, et al. Global and regional effects of bladder cancer risk associated with pioglitazone therapy in patients with diabetes. Sci Rep  2017; 7(1): 15804.
[http://dx.doi.org/10.1038/s41598-017-16074-1] [PMID:  29150684] 
[175] 
Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: A meta-analysis. Diabetes Ther  2017; 8(4): 705-26.
[http://dx.doi.org/10.1007/s13300-017-0273-4] [PMID:  28623552] 
[176] 
Li Z, Sun M, Wang F, Shi J, Wang K. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: A dose-response meta-analysis. Int J Clin Pharmacol Ther  2017; 55(3): 210-9.
[http://dx.doi.org/10.5414/CP202670] [PMID:  28025963] 
[177] 
Yan H, Xie H, Ying Y, et al. Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. Cancer Manag Res  2018; 10: 1627-38.
[http://dx.doi.org/10.2147/CMAR.S164840] [PMID:  29970962] 
[178] 
Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: A systematic review and meta-analysis. Cancer Med  2018; 7(4): 1070-80.
[http://dx.doi.org/10.1002/cam4.1354] [PMID:  29476615] 
[179] 
Adil M, Khan RA, Ghosh P, Venkata SK, Kandhare AD, Sharma M. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis of observational studies using real-world data. Clin Epidemiol Glob Health  2018; 6: 61-8.
[http://dx.doi.org/10.1016/j.cegh.2017.08.002] 
[180] 
Mehtälä J, Khanfir H, Bennett D, Ye Y, Korhonen P, Hoti F. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int  2018; 10(1): 24-36.
[http://dx.doi.org/10.1007/s13340-018-0360-4] [PMID:  30800561] 
[181] 
Davidson MB, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract  2018; 135: 102-10.
[http://dx.doi.org/10.1016/j.diabres.2017.11.002] [PMID:  29146119] 
[182] 
Rothman KJ. Induction and latent periods. Am J Epidemiol  1981; 114(2): 253-9.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a113189] [PMID:  7304560] 
[183] 
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID:  30207593] 
[184] 
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA  2011; 306(7): 737-45.
[http://dx.doi.org/10.1001/jama.2011.1142] [PMID:  21846855] 
[185] 
Chen HI, Liou SH, Loh CH, Uang SN, Yu YC, Shih TS. Bladder cancer screening and monitoring of 4,4'-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology  2005; 66(2): 305-10.
[http://dx.doi.org/10.1016/j.urology.2005.02.031] [PMID:  16098360] 
[186] 
Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: An updated meta-analysis of 36 observational studies. BMC Cancer  2013; 13: 310.
[http://dx.doi.org/10.1186/1471-2407-13-310] [PMID:  23803148] 
[187] 
Montella M, Di Maso M, Crispo A, et al. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: A case-control study. BMC Cancer  2015; 15: 720.
[http://dx.doi.org/10.1186/s12885-015-1769-9] [PMID:  26475132] 
[188] 
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care  2015; 38(1): 140-9.
[http://dx.doi.org/10.2337/dc14-2441] [PMID:  25538310] 
[189] 
American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2021. Diabetes Care  2021; 44(Suppl. 1): S111-24.
[http://dx.doi.org/10.2337/dc21-S009] [PMID:  33298420] 
[190] 
Aschenbrenner DS. Updated review confirms potential risk of bladder cancer with pioglitazone. Am J Nurs  2017; 117(4): 25.
[http://dx.doi.org/10.1097/01.NAJ.0000515230.35655.54] [PMID:  28333739] 
[191] 
Glover R. Review: The presumption of innocence: Evidential and human rights perspectives. IJE & P  2011; 15(1): 89-92.
[http://dx.doi.org/10.1350/ijep.2011.15.1.371] 
[192] 
Smith CM. Origin and uses of primum non nocere-above all, do no harm! J Clin Pharmacol  2005; 45(4): 371-7.
[http://dx.doi.org/10.1177/0091270004273680] [PMID:  15778417] 
[193] 
Ernst E. Medicines guilty until proven innocent. Pharm J  2005; 274(7352): 679.
[194] 
Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke  2017; 48(2): 388-93.
[http://dx.doi.org/10.1161/STROKEAHA.116.013977] [PMID:  27999139] 
[195] 
Satirapoj B, Watanakijthavonkul K, Supasyndh O. Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial. PLoS One  2018; 13(10): e0206722.
[http://dx.doi.org/10.1371/journal.pone.0206722] [PMID:  30379936] 
[196] 
Yanai H, Adachi H. The low-dose (7.5 mg/day) pioglitazone therapy. J Clin Med Res  2017; 9(10): 821-5.
[http://dx.doi.org/10.14740/jocmr3144w] [PMID:  28912917] 
[197] 
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care  2018; 41(12): 2669-701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID:  30291106] 
[198] 
Ryder REJ, DeFronzo RA. Diabetes medications with cardiovascular protection in the wake of EMPA-REG outcome: The optimal combination may be metformin, pioglitazone and empagliflozin. Br J Diabetes Vasc Dis  2015; 15: 151-4.
[http://dx.doi.org/10.15277/bjdvd.2015.045] 
[199] 
DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder RE, Abdul-Ghani M. Revitalization of pioglitazone: The optimal agent to be combined with an SGLT2 inhibitor. Diabetes Obes Metab  2016; 18(5): 454-62.
[http://dx.doi.org/10.1111/dom.12652] [PMID:  26919068] 
[200] 
Papaetis GS. Empagliflozin therapy and insulin resistance-associated disorders: Effects and promises beyond a diabetic state. Arch Med Sci Atheroscler Dis  2021; 6: e57-78.
[http://dx.doi.org/10.5114/amsad.2021.105314] [PMID:  34027215] 
[201] 
Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease and type 2 diabetes: Has the dawn of a new era arrived? Diabetes Care  2017; 40(7): 813-20.
[http://dx.doi.org/10.2337/dc16-2736] [PMID:  28637886] 
[202] 
Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care  2012; 35(12): 2665-73.
[http://dx.doi.org/10.2337/dc12-0788] [PMID:  23173135] 
[203] 
Bykov K, He M, Franklin JM, Garry EM, Seeger JD, Patorno E. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. Diabetes Obes Metab  2019; 21(9): 2029-38.
[http://dx.doi.org/10.1111/dom.13766] [PMID:  31062453] 
[204] 
Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. Pioglitazone and bladder cancer: Improving research methods. Diabet Med  2020; 37(5): 898-9.
[http://dx.doi.org/10.1111/dme.14248] [PMID:  31995846] 
[205] 
Franklin JM, Eddings W, Austin PC, Stuart EA, Schneeweiss S. Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. Stat Med  2017; 36(12): 1946-63.
[PMID:  28208229] 
[206] 
Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab  2018; 20(4): 974-84.
[http://dx.doi.org/10.1111/dom.13184] [PMID:  29206336] 
[207] 
Walker JJ, Johnson JA, Wild SH. Diabetes treatments and cancer risk: The importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol  2013; 1(2): 132-9.
[http://dx.doi.org/10.1016/S2213-8587(13)70028-7] [PMID:  24622319] 
Cite As
Current Drug Safety

Pioglitazone, Bladder Cancer, and the Presumption of Innocence

Abstract

Graphical Abstract
